Lisa Deschamps, CEO

April 13 | 2:00pm | Dark Horse Consulting Ballroom 

London, United Kingdom


AviadoBio’s mission is to develop and deliver potentially transformative gene therapies for people living with devastating neurodegenerative diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. AviadoBio has developed a next-generation AAV gene therapy platform focused on controlling gene expression and is complemented by a suite of unique delivery solutions to deliver gene therapies directly to the brain and spinal cord. Our rich heritage in academia complemented by a strong leadership team with extensive gene therapy development and commercialization experience uniquely positions AviadoBio for success in bringing transformative medicines to patients.


By using this website you agree to accept our Privacy Policy and Terms & Conditions